Lilly's Carelessness in Discontinuing 3 mL vials of Humalog Causes Shortages in 10 mL vials of Humalog + Unbranded Lispro
Last week, the JDRF shared newshttps://x.com/JDRF/status/1770848177354137650 in a series of three Tweets about how Eli Lilly& Company, Inc. was reporting that 10 mL vials of Humalog and the company ' s identical, unbranded (meaning Lilly sells it using the generic drug name rather than brand-name Humalog) version of Humalog known as Lilly Insulin Lispro Injection could be facing temporary lack of availability in selected locations around the country. Lilly tried to reassure everyone that it was only a temporary issue. But while Lilly complains it cannot keep up with demand for Mounjaro/Zepbound, it is having its own su...
Source: Scott's Web Log - April 9, 2024 Category: Endocrinology Tags: Eli Lilly and Company 2024 Humalog lispro vials Source Type: blogs
Patient Advocates Argue Exercising Bayh-Dole " March-In " Rights Reasonable to Ensure Ongoing Supply of an Insulin Novo Nordisk Intends to Discontinue
Back in 2016 (when President Obama was still in office), the trade group known as the Pharmaceutical Research and Manufacturers of America (better known by the acronym PhRMA) claimed in an organization-published white paper (seehttps://web.archive.org/web/20161022175500/https://phrma.org/sites/default/files/pdf/bayh-dole-act-white-paper-summary.pdf for an archived copy of that paper from PhRMA; note that it has since been removed from PhRMA ' s website, hence I found a copy on the Internet Archive) that championed the Bayh-Dole Act of 1980. Understand that what PhRMA really wants to prevent a particular provision...
Source: Scott's Web Log - February 11, 2024 Category: Endocrinology Tags: march-in rights 2024 Alliance to Protect Insulin Choice APIC Bayh-Dole insulin detemir Levemir Novo Nordisk Source Type: blogs
The Business Case for a Biosimilar Company to Bring a Copy of Levemir to Market
My readers may recall that in November 2023, I blogged that Novo Nordisk announced it plans to retire (stop making) its first " Lantus killer " known as Levemir (insulin detemir injection) in the U.S. in 2024 (catch my post at https://blog.sstrumello.com/2023/11/novo-nordisk-to-discontinue-levemir-in.html for more). At the time I learned of the announcement, I was on vacation in Amsterdam, so I just made a note of the development and blogged about it a few weeks later upon my return.Like other patients my age, I have endured the company ' s previous insulin " retirements " . Novo Nordisk ' s time-frame for withdr...
Source: Scott's Web Log - January 25, 2024 Category: Endocrinology Tags: 2024 Biosimilar Levemir Novo Nordisk PBM Source Type: blogs
Novo Nordisk to Discontinue Levemir in 2024
Upgrade to Patent-Protected Tresiba — or else!On Wednesday, November 8, 2023, Novo Nordisk announced that it would discontinue its long-acting insulin Levemir (insulin detemir injection) in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The company ' s official statement (seehttps://www.novomedlink.com/diabetes/products/treatments/levemir.html) said: " We will continue to provide Levemir FlexPen and Levemir vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected. "It added further: " Levemir FlexPen,...
Source: Scott's Web Log - November 29, 2023 Category: Endocrinology Tags: 2023 basal insulin diatribe discontinue insulin detemir Levemir Novo Nordisk Source Type: blogs
What's new in midwifery - mostly COVID related
The last collection of things you may want to know about. Firstly, COVID related:Asystematic review and meta-analysis of neonatal outcomes of COVID-19 vaccination in pregnancy, published in Pediatric Research.Another,of the effectiveness and safety of COVID-19 vaccine in pregnant women, published in BJOG.Then, apopulation based matched cohort study of major congenital anomalies following COVID-19 vaccination and SARS-CoV-2 infection - two separate groups, using health records from Scotland, published in Nature Communications.Anda sequential prospective meta-analysis of clinical risk factors of adverse outcomes a...
Source: Browsing - January 26, 2023 Category: Databases & Libraries Tags: midwifery Source Type: blogs
Novo Nordisk Will Sell An Unbranded Version of Tresiba in the U.S.
Sometimes communicating the right message to the right party at the right time may result in a pleasantly unexpected thing happening!During this year ' s EASD which took place in Stockholm, Sweden (a beautiful city I ' ve visited more than a few times over the years), at the end of a Live Tweet event with Novo Nordisk Live@NovoNordiskLive, I shared a few thoughts which had been bothering me about Novo Nordisk ' s commitment to its U.S. unbranded insulin strategy (I described its commitment as " half-hearted " ), and I did so by sharing several slide images which I got directly from Novo Nordisk ' s quarterly investor prese...
Source: Scott's Web Log - September 29, 2022 Category: Endocrinology Tags: authorized generic insulin analogs 2022 authorized generics Inc. Novo Nordisk Pharma unbranded insulin Source Type: blogs
Civica Rx: We're Entering the U.S. Insulin Biosimilar Business!
This morning, I woke up and unplugged my phone from its charger, and went to close Twitter (which I forgot to close last night before I went to bed) and at the top was a press release from Civica Rx. The press release is here: Civica to Manufacture and Distribute Affordable Insulinhttp://dlvr.it/SL0QZV The news was greeted as a welcome development by JDRF, Beyond Type 1 and the Helmsley Charitable Trust to name a few. The ADA said nothing formally about it as of 10:00 AM. In essence, Civica Rx says it plans to sell biosimilar versions of Lantus, Humalog and Novolog. As usual, there ' s a lot of details unpack her...
Source: Scott's Web Log - March 3, 2022 Category: Endocrinology Tags: 2022 Biocon Biosimilar biosimilars Civica Rx CivicaRx insulin Viatris Source Type: blogs
Insulin in the Human Body
You're reading Insulin in the Human Body, originally posted on Pick the Brain | Motivation and Self Improvement. If you're enjoying this, please visit our site for more inspirational articles.
What is insulin?
To do the tasks, the body needs energy and sugar can be considered a good source of energy to be obtained from inside. As a matter of fact, sugar cannot be directly reached to most of your cells. Thus, there are cells emitted from the pancreas, which will release the sugar in the human body which is termed as insulin.
Insulin is a hormone that is secreted by the pancreas that is responsible for the regulation ...
Source: PickTheBrain | Motivation and Self Improvement - August 2, 2019 Category: Consumer Health News Authors: Chandan Singh Tags: health and fitness Source Type: blogs
Human insulin may be a lower-cost option for some people with diabetes
Of the estimated 23 million people in the US who have been diagnosed with diabetes, more than 30% take daily insulin injections to control their blood sugar (glucose) levels. Chances are good that someone you know has been startled by the high cost of this medication.
The high price of insulin
Prices for this essential medication have been rising faster than overall health care costs. From 2002 to 2013 prices tripled, doubling again from 2012 to 2016 and continuing upward since. Patients can be charged hundreds or even thousands of dollars for insulin at the pharmacy. And insulin costs can vary depending on type and amount...
Source: Harvard Health Blog - June 3, 2019 Category: Consumer Health News Authors: Elizabeth Bashoff, MD Tags: Diabetes Drugs and Supplements Health Source Type: blogs
Pre-authorization is hell. Here ’s why.
This April, my turn to take the medical board exam rolled back around, necessary every ten years for maintenance of certification. I studied diligently for the better part of three months preceding the test (and I think I did well). It was actually pleasurable to go back over details that I had forgotten and to catch up on newer developments in the field. I realized that I don’t do nearly as much studying, or reading the medical literature as I once did. I used to read an article or two and browse the general medical literature for updates on a daily basis. But my priorities have changed over the last few years.
Now, ins...
Source: Kevin, M.D. - Medical Weblog - July 5, 2017 Category: General Medicine Authors: < a href="http://www.kevinmd.com/blog/post-author/matthew-hahn" rel="tag" > Matthew Hahn, MD < /a > Tags: Meds Medications Source Type: blogs
Novo Nordisk Settles Qui Tam Suit
Novo Nordisk is in the midst of settling a whistleblower lawsuit that alleges that the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza, and Levemir. The complaint was recently unsealed as part of the settlement process and alleges that Novo Nordisk partnered up with a clinical education company, Healthstar’s PT, to set up a program – “Changing Life with Diabetes” – which hired and trained certified diabetes educators.
The whistleblowers, two former managers, claim that since 2006, Novo ran the program to gain access to physician practices, where the educators would provide th...
Source: Policy and Medicine - May 5, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Novo's Ills Are Indicative of Something Other Than A Free Market for Insulin
As I ' ve already addressed, a few weeks ago (see my post athttp://blog.sstrumello.com/2016/08/the-business-of-diabetes-cvs-caremarks_5.html for more), Novo Nordisk ' s CEO Lars Rebien Sorensen rather unceremoniously announced he was retiring early (see http://fortune.com/2016/09/01/novo-nordisk-ceo-retire-insulin/ for more) which was kind of an acknowledgement that the era of easy price increases for its products in the U.S. is over. Already, CVS Caremark and United Health announced that they are dropping Sanofi ' s Lantus in favor of biosimilar versions from Lilly/Boehringer or Merck/Samsung, and there ' s...
Source: Scott's Web Log - September 30, 2016 Category: Endocrinology Tags: 2016 Biosimilar generic insulin Novo Nordis PBM prices Source Type: blogs
Novo's Ills Are Indicative of Something Other Than A Free Market for Insulin
As I ' ve already addressed, a few weeks ago (see my post athttp://blog.sstrumello.com/2016/08/the-business-of-diabetes-cvs-caremarks_5.html for more), Novo Nordisk ' s CEO Lars Rebien Sorensen rather unceremoniously announced he was retiring early (see http://fortune.com/2016/09/01/novo-nordisk-ceo-retire-insulin/ for more) which was kind of an acknowledgement that the era of easy price increases for its products in the U.S. is over. Already, CVS Caremark and United Health announced that they are dropping Sanofi ' s Lantus in favor of biosimilar versions from Lilly/Boehringer or Merck/Samsung, and there ' s...
Source: Scott's Web Log - September 30, 2016 Category: Endocrinology Tags: 2016 Biosimilar generic insulin Novo Nordis PBM prices Source Type: blogs
The Business of Diabetes: CVS Caremark's Salvo in Biosimilar Insulin for 2017
Its already mid-2016, and for nearly the past decade, I ' ve been pushing for so-called " biosimilars " or " follow-on biologics " like insulin to be legalized and then introduced in the U.S. (I first investigated this issue back in 2006, and published anarticle on it in January 2007). The reality is that without any form of generic competition, prices continue to rise with absolutely nothing to stop them. In recent years, there have been some hyper-aggressive price-increases from the insulin oligopoly, especially within the last 3 years or so. The reason: they all KNOW that their insulin analog patents are about...
Source: Scott's Web Log - August 5, 2016 Category: Endocrinology Tags: Biosimilar insulin Lantus Lilly Merck Source Type: blogs
